Canadian Technology Stocks
Everywhere you look, food is news. From the government of Algeria increasing wheat supplies after food riots, to food price inflation in India deterring foreign investors to the suicide of a Tunisian fruit seller sparking a revolution. When you can offer tangible improvements to a business that might be the most important on the planet, [...]
In British Columbia, Glentel’s roots run deep. After closing the year near the $25 mark, nearly double where it began 2010, casual observers could be excused for imagining that the Burnaby based “Wireless Wave” operator has always been firmly ensconced as a leader here. But Glentel’s story has more twists and turns than the Fraser River, which empties into the Pacific a few miles from the company’s head office. Cantech Letter’s Nick Waddell sat down with Glentel CEO Tom Skidmore to talk about this past and the pheneomenal year the company had. Oh, and to present Glentel with Cantech Letter’s 2010 Canadian Tech Stock of the Year.
It’s been nearly a century since Canada’s greatest achievement in biotech took place; the discovery of insulin by Frederick Banting and his assistant Charles Best, in 1922. While nothing since has matched that miraculous feat, which has saved countless millions of lives, it’s not like Canada has been sitting still in the meantime. Canadian researchers have contributed to The Human Genome project, cracked the genetic code of the mosquito that carries the deadliest strain of malaria, and deciphered human chromosome 7, which holds the gene for cystic fibrosis. Our December issue is about Canadian Life Sciences stocks carrying the torch of innovation.
Calgary’s Oncolytics Biotech grew out of discoveries made in the 1990′s in the Department of Microbiology and Infectious Diseases at the University of Calgary. The Company’s Reolysin, a formulation of reovirus, a family of viruses that can affect the gastrointestinal system and have shown to have oncolytic, or cancer killing properties, is about to enter [...]
If you’ve ever tried to choke down a series of pills while laid up in a hospital bed, you know it can be inconvenient. Quebec’s IntelGenx has a solution for that and for a host of other ineffificiences related to current drug delivery methods. You’re probably already somewhat familiar with IntelGenx Quick Release Wafer Technology, [...]
We’re always reminded that health care costs are spiraling, we’re less often reminded of exactly why. One number might surprise: the Center for Disease Control estimates that the financial burden attributable to healthcare associated infections is between $28 and $33 billion. The trouble? Antibiotics. Patients with infections take a series of antibiotics, but the infections [...]
Halifax based Immunovaccine‘s slogan is “Delivering Breakthrough Vaccines”. Look into Immunovaccine’s technology and you’ll quickly realize the accent in this phrase is clearly on the word delivering. Immunovaccine is based around the idea that the delivery method of vaccines may be of greater importance to their success than had previously been suspected by the medical [...]
You could hear a pin drop. Shareholders of Resverlogix waited with baited breath for November 17th. That was the day that Resverlogix President and CEO Donald McCaffrey was to present data from the company’s ASSURE trial. In that study, which was completed earlier this year, just under three hundred patients with coronary artery disease took [...]
The debate over whether carbon offsets work in the real world is a long, complicated and, ultimately, incomplete one. Some argue that the concept of ‘additionality”, the idea that the consumer is unaware whether an offset solution would have happened regardless of the additional funds, renders the market ripe for scandal. Others say carbon offsets [...]
In the past five years broadcast technology has, arguably, advanced more than in the previous fifty. Last November, Fred Godard and Adam Adamou were two-thirds of an investor group that acquired about 20% of Ottawa’s International Datacasting (TSX:IDC), a more than two decades old broadcast technology firm that had appeared to have leveled off. Less than a year later, with Godard in place as President and CEO and Adamou as Executive Chairman, IDC reported one of its best quarters ever. We sat down with Adam and Fred to talk about the company Adamou calls a “25 year old startup”.
